- Home
- GNLX vs YARW Comparison
GNLX vs YARW Comparison
Compare GNLX & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | YARW |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.0M | 111.2M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GNLX | YARW |
|---|---|---|
| Price | $2.67 | $42.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 226.5K | 20.8K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.29 | $31.55 |
| 52 Week High | $8.54 | $42.50 |
Technical Indicators
Market Signals| Indicator | GNLX | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | N/A |
| Support Level | $2.68 | N/A |
| Resistance Level | $3.05 | N/A |
| Average True Range (ATR) | 0.18 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 34.48 | 0.00 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.